REDX Redx Pharma Plc

TIDMREDX

Redx Pharma plc

15 May 2017

15 May 2017

AIM: REDX

Abstract #219

Poster #210

REDX PHARMA PLC

("Redx" or "the Company")

Preclinical data for reversible BTK inhibitor RXC005 presented at the 17(th) International Workshop of Chronic Lymphocytic Leukemia

Redx Pharma, the research and development company focused on cancer, immunology and infection, announces that preclinical efficacy data in mouse-models for its development candidate, RXC005, a reversible BTK inhibitor, has been presented in a poster session at the 17(th) International Workshop of Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York City, U.S. on 14 May, 2017.

The poster, entitled "RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models", demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-Cell Receptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.

RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines.

The poster can be found on the Company's website www.redxpharma.com

Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented: "We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries."

Dr Richard Armer, Chief Scientific Officer of Redx Pharma, commented: "The data presented is further validation of RXC005's potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment. With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic."

For further information, please contact:

 
Redx Pharma Plc 
Neil Murray, Chief Executive Officer       T: +44 1625 
                                               469 900 
Karl Hård, Head of IR & Corporate     T: +44 7491 
 Communications                                651 406 
Cantor Fitzgerald Europe (Nomad & Broker)    T: +44 20 
                                             7894 7000 
Phil Davies/ Michael Reynolds 
 
WG Partners LLP (Joint Broker)               T: +44 20 
                                             3705 9330 
Claes Spång/ Chris Lee/ David 
 Wilson 
 
  Consilium Strategic Communications         T: +44 20 
                                             3709 5700 
Amber Fennell/ Matthew Neal/ Melissa 
 Gardiner 
 

About Redx Pharma Plc

Company website: www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, immunology and infection providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAAIMBTMBBBTAR

(END) Dow Jones Newswires

May 15, 2017 02:00 ET (06:00 GMT)

Redx Pharma (LSE:REDX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2023 to Apr 2024